| Drug General Information |
| Drug ID |
D0R0FO
|
| Former ID |
DCL000786
|
| Drug Name |
E 7080
|
| Synonyms |
E7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide
|
| Drug Type |
Small molecular drug
|
| Indication |
Ovarian cancer [ICD9: 183; ICD10:C56]
|
Phase 1 |
[1]
|
|---|
| Company |
Eisai Co. Ltd.
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C21H19ClN4O4
|
| Canonical SMILES |
COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC<br />4)Cl
|
| InChI |
1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)
|
| InChIKey |
WOSKHXYHFSIKNG-UHFFFAOYSA-N
|
| CAS Number |
CAS 204460-24-2
|
| PubChem Compound ID |
|
| PubChem Substance ID |
14782907, 24126764, 44859775, 74753053, 99436922, 123098996, 123110209, 124757043, 125163847, 125749042, 126665901, 131314303, 131480711, 134221774, 135262444, 135626656, 135685148, 135685149, 135685168, 136367339, 136367958, 137262627, 137276042, 139802275, 144115929, 152258284, 152344144, 160647123, 162011787, 162037768, 162527769, 164041901, 174560999, 178103998, 180386840, 198978519, 202553041, 223669921, 223705252, 223913134, 227134592, 242060265, 247802696, 251911433, 251971223, 252150297, 252215326, 252215327, 252451828, 252543308
|
| Target and Pathway |
| Target(s) |
Vascular endothelial growth factor receptor 2 |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Proteoglycans in cancer
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
S1P1 pathway
|
|
VEGF and VEGFR signaling network
|
|
Integrins in angiogenesis
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Notch-mediated HES/HEY network
|
|
Reactome
|
Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerization
|
|
Integrin cell surface interactions
|
|
EPHA-mediated growth cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
VEGFR2 mediated cell proliferation
|
|
WikiPathways
|
Focal Adhesion
|
|
Nifedipine Activity
|
|
Cardiac Progenitor Differentiation
|
|
Signaling by VEGF
|
|
Angiogenesis
|
| References |
| REF 1 | Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36. |
|---|
